Jerini expands collaboration with Baxter to develop non-intraveneous hemophilia therapy
Jerini AG announced the expansion of their current research collaboration with Baxter AG for the development of a non-intravenous therapy for the treatment of hemophilia. The companies have initiated two additional programs aimed at novel targets, potentially offering new therapeutic developments in the treatment of hemophilia. These new agreements, along with the existing collaboration, focus on three specific targets associated with the disease.
Under the terms of the expanded agreement, Jerini will receive upfront payments and full time equivalents (FTE) funding for each of the two new programs, with potential milestone payments for the achievement of discovery, preclinical, and clinical goals as well as royalties on eventual product sales. The original collaboration between Baxter and Jerini was initiated in 2001 and expanded in 2004.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.